SKINBIOTIX LIMITED

Active Newcastle Upon Tyne

Other human health activities

0 employees website.com
Life sciences and medical technology Other human health activities
S

SKINBIOTIX LIMITED

Other human health activities

Founded 5 Jan 2017 Active Newcastle Upon Tyne, England 0 employees website.com
Life sciences and medical technology Other human health activities
Accounts Submitted 25 Mar 2026 Next due 31 Mar 2026 3 months overdue
Confirmation Submitted 14 Jan 2026 Next due 18 Jan 2027 7 months remaining
Net assets £1 £0 2025 year on year
Total assets £1 £0 2025 year on year
Total Liabilities £0
Charges None No charges registered

Contact & Details

Contact

Registered Address

The Core Bath Lane Newcastle Helix Newcastle Upon Tyne NE4 5TF England

Telephone

0800 000 0000

Website

www.example.com

Full company profile for SKINBIOTIX LIMITED (10549152), an active life sciences and medical technology company based in Newcastle Upon Tyne, England. Incorporated 5 Jan 2017. Other human health activities. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jul → 30 Jun 2025
Type dormant
Next accounts 30 Jun 2025
Due by 31 Mar 2026 3 months overdue

Net Assets, Total Assets & Total Liabilities (2017–2025)

Cash in Bank

£1.00

Net Assets

£1.00

Total Liabilities

N/A

Turnover

N/A

Employees

N/A

Debt Ratio

N/A

Financial History

Revenue, profit, EBITDA and key financial figures

2025
30 Jun Year End
2024
30 Jun Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

1 active 2 resigned
Status
Simon Jonathan HewitsonDirectorBritishUnited Kingdom5028 Apr 2025Active

Shareholders

Shareholders (1)

Skinbiotherapeutics Plc
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Active
Notified 5 Jan 2017
Nature of Control
  • Ownership Of Shares 75 To 100 Percent

Group Structure

Group Structure

SKINBIOTIX LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
25 Mar 2026AccountsAnnual accounts made up to 30 Jun 2025
20 Mar 2026OfficersAppointment of Mrs Rachel Lisa Parsonage as director on 9 Mar 2026
13 Feb 2026OfficersTermination of Stuart John Ashman as director on 13 Feb 2026
14 Jan 2026Confirmation StatementConfirmation statement made on 4 Jan 2026 with no updates
14 Jan 2026OfficersAppointment of Mrs Emily Lorraine Bertram as director on 1 Jan 2026
25 Mar 2026 Accounts

Annual accounts made up to 30 Jun 2025

20 Mar 2026 Officers

Appointment of Mrs Rachel Lisa Parsonage as director on 9 Mar 2026

13 Feb 2026 Officers

Termination of Stuart John Ashman as director on 13 Feb 2026

14 Jan 2026 Confirmation Statement

Confirmation statement made on 4 Jan 2026 with no updates

14 Jan 2026 Officers

Appointment of Mrs Emily Lorraine Bertram as director on 1 Jan 2026

Recent Activity

Latest Activity

Annual accounts made up to 30 Jun 2025

2 months ago on 25 Mar 2026

Appointment of Mrs Rachel Lisa Parsonage as director on 9 Mar 2026

2 months ago on 20 Mar 2026

Termination of Stuart John Ashman as director on 13 Feb 2026

3 months ago on 13 Feb 2026

Confirmation statement made on 4 Jan 2026 with no updates

4 months ago on 14 Jan 2026

Appointment of Mrs Emily Lorraine Bertram as director on 1 Jan 2026

4 months ago on 14 Jan 2026